BA
RETA

BlackRock Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

BlackRock Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$46K Sell
2,097
-90
-4% -$2.28K ﹤0.01% 3278
2016
Q3 		$58K Sell
2,187
-5,229
-71% -$104K ﹤0.01% 3205
2016
Q2 		$146K Buy
+7,416
New +$144K ﹤0.01% 2781

Other funds holding RETA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's RETA Position: Q4 2016 in Review

BlackRock Advisors reduced its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 4.1% in Q4 2016, selling an estimated $2.28K and leaving 2,097 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #3278.

BlackRock Advisors first reported a position in RETA in Q2 2016 and has held it in 3 quarters since. The position peaked at $146K in Q2 2016. 52 funds tracked by Wall St. Rank hold RETA as of Q4 2016.

  • BlackRock Advisors held 2,097 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $46K as of Q4 2016.
  • BlackRock Advisors sold 90 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2016, an estimated $2.28K.
  • Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3278 holding.
  • BlackRock Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $146K in Q2 2016.
  • 52 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.